MedPath

M.D. ANDERSON CANCER CENTER

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Resting-State Functional MRI in Glioma Patients Before and After Surgery

Not Applicable
Completed
Conditions
Brain Mass
Glioma
Interventions
Procedure: Functional Magnetic Resonance Imaging
Procedure: Magnetic Resonance Imaging
Procedure: Resting State Functional Connectivity Magnetic Resonance Imaging
First Posted Date
2019-05-28
Last Posted Date
2024-11-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
29
Registration Number
NCT03964909
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas

Phase 1
Completed
Conditions
Meningioma
Interventions
Procedure: Computed Tomography
Radiation: Gallium Ga 68-DOTATATE
Procedure: Positron Emission Tomography
First Posted Date
2019-05-16
Last Posted Date
2023-09-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
13
Registration Number
NCT03953131
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Dietary Intervention in Patients with a History of Melanoma

Phase 1
Terminated
Conditions
Melanoma
Interventions
Dietary Supplement: Dietary Intervention
Other: Questionnaire Administration
First Posted Date
2019-05-15
Last Posted Date
2024-12-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
13
Registration Number
NCT03950635
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Phase 2
Active, not recruiting
Conditions
Advanced Carcinoid Tumor
Digestive System Neuroendocrine Neoplasm
Multiple Endocrine Neoplasia Type 1
Neuroendocrine Neoplasm
Unresectable Carcinoid Tumor
Interventions
First Posted Date
2019-05-15
Last Posted Date
2025-01-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
36
Registration Number
NCT03950609
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

Not Applicable
Recruiting
Conditions
Stage IIIA Lung Cancer AJCC v8
Esophageal Carcinoma
Stage I Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Stage IA1 Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Interventions
Other: Educational Intervention
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Yoga
First Posted Date
2019-05-13
Last Posted Date
2024-08-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
400
Registration Number
NCT03948100
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2
Active, not recruiting
Conditions
CCND1 Protein Overexpression
Blastoid Variant Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
t(11;14)(q13;q32)
FCER2 Negative
CD20 Positive
CD5 Positive
Pleomorphic Variant Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
Interventions
First Posted Date
2019-05-13
Last Posted Date
2024-10-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
32
Registration Number
NCT03946878
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Early Phase 1
Active, not recruiting
Conditions
BRCA-Mutated Ovarian Carcinoma
BRCA1 Gene Mutation
BRCA2 Gene Mutation
Stage IIIA Ovarian Cancer AJCC v8
High Grade Fallopian Tube Serous Adenocarcinoma
Stage III Fallopian Tube Cancer AJCC v8
High Grade Ovarian Serous Adenocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Stage III Primary Peritoneal Cancer AJCC v8
Stage IIIA1 Fallopian Tube Cancer AJCC v8
Interventions
Drug: Chemotherapy
Drug: Olaparib
Procedure: Therapeutic Conventional Surgery
First Posted Date
2019-05-09
Last Posted Date
2024-07-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
15
Registration Number
NCT03943173
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

Not Applicable
Recruiting
Conditions
Breast Inflammatory Carcinoma
Anatomic Stage III Breast Cancer AJCC v8
Locally Advanced Breast Carcinoma
Melanoma
Interventions
Drug: Indocyanine Green
Procedure: Lymphangiography
Procedure: Lymphovenous Bypass
First Posted Date
2019-05-08
Last Posted Date
2024-12-06
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
252
Registration Number
NCT03941756
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myeloproliferative Neoplasm
Cord Blood Transplant Recipient
Interventions
First Posted Date
2019-05-08
Last Posted Date
2024-10-17
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
1
Registration Number
NCT03941769
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Correlating MicroRNA Changes with Sepsis Outcomes

Active, not recruiting
Conditions
Septicemia
Interventions
Procedure: Biospecimen Collection
First Posted Date
2019-04-26
Last Posted Date
2024-10-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
150
Registration Number
NCT03929159
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath